Chemopreventive effects of a selective cyclooxygenase-2 inhibitor (etodolac) on chemically induced intraductal papillary carcinoma of the pancreas in hamsters

Carcinogenesis

Volumn 29, Issue 4, 2008, Pages 830-833

  Adachi, Tomohiko ^a   Tajima, Yoshitsugu ^a   Kuroki, Tamotsu ^a   Mishima, Takehiro ^a   Kitasato, Amane ^a   Tsuneoka, Noritsugu ^a   Kanematsu, Takashi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIS(2 OXOPROPYL)NITROSAMINE; CYCLINE; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CELL KINETICS; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYSTADENOCARCINOMA; DIETARY INTAKE; DRUG DOSE INCREASE; DRUG MECHANISM; EPITHELIUM CELL; FEMALE; HAMSTER; HISTOPATHOLOGY; INTRADUCTAL PAPILLARY PANCREAS CARCINOMA; NONHUMAN; PANCREAS CARCINOMA; PANCREAS DUCT; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

ADENOCARCINOMA, PAPILLARY; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CRICETINAE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; ETODOLAC; FEMALE; KINETICS; MESOCRICETUS;

EID: 41849096731     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn047     Document Type: Article

References (30)

1. Hruban,R.H. et al. (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol., 28, 977-987.
2. Ohhashi,K. et al. (1982) Four cases of mucous secreting pancreatic cancer. Prog. Dig. Endosc., 20, 348-351.
3. Kloppel,G. et al. (2001) WHO-classification 2000: Exocrine pancreatic tumors. Verh. Dtsch. Ges. Pathol., 85, 219-228.
4. Tanaka,M. et al. (2006) International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology, 6, 17-32.
5. Kokawa,A. et al. (2001) Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer, 91, 333-338.
6. Niijima,M. et al. (2002) Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer, 94, 1565-1573.
7. Aoki,T. et al. (2002) Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors. Oncol. Rep., 9 761-765.
8. Hu,P.J. et al. (2004) Chemoprevention of gastric cancer by celecoxib in rats. Gut, 53, 195-200.
9. Ricchi,P. et al. (2003) Nonsteroidal anti-inflammatory drugs in colorectal cancer: From prevention to therapy. Br. J. Cancer, 88, 803-807.
10. Adachi,T. et al. (2006) Bile-reflux into the pancreatic ducts is associated with the development of intraductal papillary carcinoma in hamsters. J. Surg. Res., 136, 106-111.
11. Takahashi,M. et al. (1977) The pancreas of the Syrian hamster (Mesocricetus auratua). Lab. Anim Sci., 27, 336.
12. Rinderknecht,H. et al. (1983) Pancreatic secretory profiles of protein, digestive, and lysosomal enzymes in Syrian golden hamster. Effect of secretin and cholecystokinin. Dig. Dis. Sci., 28, 518.
13. Pour,P.M. et al. (1996) Tumours of the pancreas. IARC Sci. Publ., 126, 149.
14. Eberhart,C.E. et al. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183-1188.
15. Ristimaki,A. et al. (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res., 57, 1276-1280.
16. Zimmermann,K.C. et al. (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res., 59, 198-204.
17. Tsujii,M. et al. (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83, 493-501.
18. Tsujii,M. et al. (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl Acad. Sci. USA, 94, 3336-3340.
19. Tsujii,M. et al. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93, 705-716.
20. Molina,M.A. et al. (1999) Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res., 59, 4356-4362.
21. El-Rayes,B.F. et al. (2004) Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther., 23, 1421-1426.
22. Furukawa,F. et al. (2003) A cyclooxygenase-2 inhibitor, nimesulide, inhibits postinitiation phase of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters. Int. J. Cancer, 104, 269-273.
23. Schuller,H.M. et al. (2002) The cyclooxygenase inhibitor ibuprofen and the FLAP inhibitor MK886 inhibit pancreatic carcinogenesis induced in hamsters by transplacental exposure to ethanol and the tobacco carcinogen NNK. J. Cancer Res. Clin. Oncol., 128, 525-532.
24. Crowell,P.L. et al. (2006) Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia, 8, 437-445.
25. Yip-Schneider,M.T. et al. (2000) Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis, 21, 139-146.
26. Larsson,S.C. et al. (2006) Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: A meta-analysis. Cancer Epidemiol. Biomarkers Prev., 15, 2561-2564.
27. El-Rayes,B.F. et al. (2005) A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest. New Drugs, 23, 583-590.
28. Oshima,M. et al. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
29. Maire,F. et al. (2002) Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut, 51, 717-722.
30. Sun,Y. et al. (2002) Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res, 62 6323-6328.